Description: Como aliviar a dor e melhorar o cisto de Baker no joelho. Como Aliviar o Cisto de Baker com Exercícios Fisioterapêuticos em Casa Se você sente dor atrás do joelho, percebeu um inchaço ou ...
Record News: Cisto e abscesso: quando ignorar uma ferida pode ser perigoso
The purpose of CISTO is to conduct a large prospective study that directly compares the impact of medical management versus bladder removal in recurrent high-grade NMIBC patients with BCG (Bacillus Calmette-Guerin) failure on clinical outcomes and patient and caregiver experience using standardized patient-reported outcomes (PROs).
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancer
Notably, CISTO is the only ongoing prospective study that includes radical cystectomy as a comparator to bladder-sparing treatment strategies. CISTO was a prospective observational cohort study designed to compare health-related quality of life (QOL) and clinical outcomes in patients with recurrent high-grade NMIBC.
The CISTO (Comparison of Intravesical Therapy and Surgery as Treatment Options) Study aims to address this critical knowledge gap by comparing outcomes between patients undergoing BST and radical cystectomy. Methods: The CISTO Study is a pragmatic, prospective observational cohort trial across 36 academic and community urology practices in the US.
The CISTO study remains ongoing to assess longer-term outcomes. “Radical cystectomy, as demonstrated by the CISTO study, has and should continue to have an important role in the management of recurrent high-grade non–muscle invasive bladder cancer,” Gore concluded during the presentation.
Abstract INTRODUCTION AND OBJECTIVE: Radical cystectomy (RC) and bladder-sparing therapy (BST) are established options for recurrent high-grade non-muscle invasive bladder cancer (NMIBC), but their comparative effectiveness is unclear. The CISTO Study aimed to address this gap in partnership with patients, clinicians, and other stakeholders.